Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Let us help you
Read about the latest topics.

Signing Ceremony of the "PARAMED Project"

 
Signing Ceremony of the "PARAMED Project": A Vital Reinforcement of the Public Health Sector in Lebanon
 

Under the patronage of H.E. Dr. Firass El Abiad, Mnister of Public Health, and in the presence of a delegation from the French Ministry of Health, an official signing ceremony for the "Project for Supporting the Healthcare Personnel Skills in the Public Sector in Lebanon (PARAMED)" took place in the conference room of the Ministry of Public Health (MOPH) in Jnah.  .

This project, co-financed by Agence Française de Developpement (AFD) and the IF! Foundation, and implemented by the European Institute for Cooperation and Development (IECD), aims to substantially strengthen the skills of healthcare professionals within Lebanon's public health structures.

In his speech, the Minister of Public Health, Dr. Firas El Abiad, emphasized: "The importance of this program lies in its expansion to include 12 public hospitals, after initially starting with four hospitals, with the aim of training healthcare professionals so they can provide the necessary services to our citizens, especially the most vulnerable segments of Lebanese society. This program is funded by the French Development Agency to the tune of six million euros and is implemented by the European Institute for Cooperation and Development in Lebanon." Minister Abiad continued by stating that: “This program would not have been possible without the support provided by France to Lebanon, particularly through the French Development Agency (AFD), which supports several projects in the health and education sectors. What is remarkable about this program is that it brings together the health and education sectors, with the goal of providing better healthcare services to all people on Lebanese territory.”

Mrs. Catherine Bonnaud, Country Director and Regional Director of AFD, declared that by investing in training and professional development of health workers, we strengthen not only individual capabilities, but also the resilience and effectiveness of the health system as a whole. This is a long-term investment in the health and well-being of all Lebanese citizens.

In a context of crisis affecting the Lebanese healthcare system, the PARAMED project represents a crucial initiative to improve the quality of care provided to the most vulnerable populations and facilitate access to it. The project includes, among other objectives, the establishment of training centers in 12 public hospitals and the implementation of ongoing training and refresher programs for recent graduates and existing hospital staff.
 
Mr. Vianney Basse, Director for Lebanon and the Middle East at IECD, emphasized the quality of the trust-based relationship between the Minister of Health, AFD, and IECD, and that this partnership is fully aligned with the Ministry’s 2030 Strategy. He recalled that IECD, whose mission is to support youth through vocational training projects, will strengthen its involvement in the health sector through PARAMED.

By strengthening the capacities of health professionals and promoting the employability of young men and women in the field of nursing, the PARAMED project aims to reach 4,200 healthcare workers and approximately 3 million patients. In doing so, it will help reduce gaps and improve the quality of healthcare in Lebanon.
    ...
    79
    ...
ATC Name B/G Ingredients Dosage Form Price
L01ED01 XALKORI B Crizotinib - 250mg 250mg Capsule 347,644,061 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 75mg 75mg Capsule, hard 149,227,143 L.L
L01EC03 BRAFTOVI BioTech Encorafenib - 50mg 50mg Capsule, hard 70,084,833 L.L
L01EC01 ZELBORAF B Vemurafenib - 240mg 240mg Tablet, film coated 142,041,587 L.L
L01EB04 TAGRISSO B Osimertinib - 80mg 80mg Tablet, film coated 603,192,941 L.L
L01EB02 TARESSA 150 G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 98,617,813 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 150mg 150mg Tablet, film coated 88,599,923 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 150mg 150mg Tablet 91,523,229 L.L
L01EB02 TARESSA 100 G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 82,247,256 L.L
L01EB02 MIRATA G Erlotinib (HCl) - 100mg 100mg Tablet, film coated 77,379,009 L.L
L01EB02 APO-ERLOTINIB G Erlotinib (HCl) - 100mg 100mg Tablet 79,672,726 L.L
L01EB01 GEFITINIB BIOGARAN G Gefitinib - 250mg 250mg Tablet, coated 83,306,550 L.L
L01EB01 GEFITINIB ARROW G Gefitinib - 250mg 250mg Tablet, coated 85,330,070 L.L
L01EB01 APO-GEFITINIB G Gefitinib - 250mg 250mg Tablet 87,345,820 L.L
L01EB01 IRESSA B Gefitinib - 250mg 250mg Tablet, fim coated 135,027,509 L.L
L01EA05 ICLUSIG B Ponatinib - 45mg 45mg Tablet, film coated 207,092,651 L.L
L01EA05 ICLUSIG B Ponatinib - 15mg 15mg Tablet, film coated 103,555,839 L.L
L01EA04 BOSULIF B Bosutinib - 500mg 500mg Tablet, film coated 154,453,246 L.L
L01EA04 BOSULIF B Bosutinib - 400mg 400mg Tablet, film coated 123,564,667 L.L
L01EA04 BOSULIF B Bosutinib - 100mg 100mg Tablet, film coated 35,663,747 L.L
L01EA03 TASIGNA B Nilotinib - 150mg 150mg Capsule 256,154,857 L.L
L01EA03 NILORA G Nilotinib - 200mg 200mg Capsule, hard 94,388,785 L.L
L01EA03 TASIGNA B Nilotinib - 200mg 200mg Capsule 324,819,838 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 140mg 140mg Tablet, film coated 127,364,905 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 140mg 140mg Tablet, film coated 254,729,810 L.L
L01EA02 ELPIDA G Dasatinib - 20mg 20mg Tablet, film coated 103,165,573 L.L
L01EA02 DASATINIB NEAPOLIS G Dasatinib - 20mg 20mg Tablet, film coated 103,165,573 L.L
L01EA02 DALEUBIN G Dasatinib - 20mg 20mg Tablet, film coated 82,387,571 L.L
L01EA02 APO-DASATINIB G Dasatinib - 20mg 20mg Tablet 57,771,855 L.L
L01EA02 ELPIDA G Dasatinib - 50mg 50mg Tablet, film coated 127,364,905 L.L
    ...
    79
    ...
Sitemap
© Copyrights reserved to Ministry of Public Health 2026